Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody

Anaplastic thyroid carcinoma, BRAF non-V600, NRAS, combination immunotherapy and targeted therapy, case report. Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid cancer with a mortality rate near 100%. BRAF V600 and NRAS mutations are the most common drivers of ATC. While patients with BR...

Descripción completa

Detalles Bibliográficos
Autores principales: Gui, Lin, Zhu, Yiming, Li, Xiaomo, He, Xiaohui, Ma, Tonghui, Cai, Yi, Liu, Shaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140402/
https://www.ncbi.nlm.nih.gov/pubmed/37122752
http://dx.doi.org/10.3389/fimmu.2023.1178682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140402/
https://www.ncbi.nlm.nih.gov/pubmed/37122752
http://dx.doi.org/10.3389/fimmu.2023.1178682

Ejemplares similares